Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Viral Vector Vaccines Market Insights, Forecast to 2026

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Viral Vector Vaccines Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Viral Vector Vaccines Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Viral Vector Vaccines Market Size Growth Rate by Type
    • 1.4.2 Adenovirus
    • 1.4.3 Fowlpox Virus
    • 1.4.4 Attenuated Yellow Fever
    • 1.4.5 Vaccinia Virus Vectors
    • 1.4.6 Others
  • 1.5 Market by Application
    • 1.5.1 Global Viral Vector Vaccines Market Size Growth Rate by Application
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): Viral Vector Vaccines Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Viral Vector Vaccines Industry
      • 1.6.1.1 Viral Vector Vaccines Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Viral Vector Vaccines Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Viral Vector Vaccines Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Executive Summary

  • 2.1 Global Viral Vector Vaccines Market Size Estimates and Forecasts
    • 2.1.1 Global Viral Vector Vaccines Revenue 2015-2026
    • 2.1.2 Global Viral Vector Vaccines Sales 2015-2026
  • 2.2 Viral Vector Vaccines Market Size by Region: 2020 Versus 2026
    • 2.2.1 Global Viral Vector Vaccines Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Viral Vector Vaccines Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Viral Vector Vaccines Competitor Landscape by Players

  • 3.1 Viral Vector Vaccines Sales by Manufacturers
    • 3.1.1 Viral Vector Vaccines Sales by Manufacturers (2015-2020)
    • 3.1.2 Viral Vector Vaccines Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Viral Vector Vaccines Revenue by Manufacturers
    • 3.2.1 Viral Vector Vaccines Revenue by Manufacturers (2015-2020)
    • 3.2.2 Viral Vector Vaccines Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Viral Vector Vaccines Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Viral Vector Vaccines Revenue in 2019
    • 3.2.5 Global Viral Vector Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Viral Vector Vaccines Price by Manufacturers
  • 3.4 Viral Vector Vaccines Manufacturing Base Distribution, Product Types
    • 3.4.1 Viral Vector Vaccines Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Viral Vector Vaccines Product Type
    • 3.4.3 Date of International Manufacturers Enter into Viral Vector Vaccines Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Viral Vector Vaccines Market Size by Type (2015-2020)
    • 4.1.1 Global Viral Vector Vaccines Sales by Type (2015-2020)
    • 4.1.2 Global Viral Vector Vaccines Revenue by Type (2015-2020)
    • 4.1.3 Viral Vector Vaccines Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Viral Vector Vaccines Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Viral Vector Vaccines Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Viral Vector Vaccines Revenue Forecast by Type (2021-2026)
    • 4.2.3 Viral Vector Vaccines Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Viral Vector Vaccines Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)

  • 5.1 Global Viral Vector Vaccines Market Size by Application (2015-2020)
    • 5.1.1 Global Viral Vector Vaccines Sales by Application (2015-2020)
    • 5.1.2 Global Viral Vector Vaccines Revenue by Application (2015-2020)
    • 5.1.3 Viral Vector Vaccines Price by Application (2015-2020)
  • 5.2 Viral Vector Vaccines Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Viral Vector Vaccines Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Viral Vector Vaccines Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Viral Vector Vaccines Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Viral Vector Vaccines by Country
    • 6.1.1 North America Viral Vector Vaccines Sales by Country
    • 6.1.2 North America Viral Vector Vaccines Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Viral Vector Vaccines Market Facts & Figures by Type
  • 6.3 North America Viral Vector Vaccines Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Viral Vector Vaccines by Country
    • 7.1.1 Europe Viral Vector Vaccines Sales by Country
    • 7.1.2 Europe Viral Vector Vaccines Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Viral Vector Vaccines Market Facts & Figures by Type
  • 7.3 Europe Viral Vector Vaccines Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Viral Vector Vaccines by Region
    • 8.1.1 Asia Pacific Viral Vector Vaccines Sales by Region
    • 8.1.2 Asia Pacific Viral Vector Vaccines Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Viral Vector Vaccines Market Facts & Figures by Type
  • 8.3 Asia Pacific Viral Vector Vaccines Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Viral Vector Vaccines by Country
    • 9.1.1 Latin America Viral Vector Vaccines Sales by Country
    • 9.1.2 Latin America Viral Vector Vaccines Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Viral Vector Vaccines Market Facts & Figures by Type
  • 9.3 Central & South America Viral Vector Vaccines Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Viral Vector Vaccines by Country
    • 10.1.1 Middle East and Africa Viral Vector Vaccines Sales by Country
    • 10.1.2 Middle East and Africa Viral Vector Vaccines Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Viral Vector Vaccines Market Facts & Figures by Type
  • 10.3 Middle East and Africa Viral Vector Vaccines Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Advanced Bioscience Laboratories
    • 11.1.1 Advanced Bioscience Laboratories Corporation Information
    • 11.1.2 Advanced Bioscience Laboratories Description, Business Overview and Total Revenue
    • 11.1.3 Advanced Bioscience Laboratories Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Advanced Bioscience Laboratories Viral Vector Vaccines Products Offered
    • 11.1.5 Advanced Bioscience Laboratories Recent Development
  • 11.2 Boehringer Ingelheim
    • 11.2.1 Boehringer Ingelheim Corporation Information
    • 11.2.2 Boehringer Ingelheim Description, Business Overview and Total Revenue
    • 11.2.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Boehringer Ingelheim Viral Vector Vaccines Products Offered
    • 11.2.5 Boehringer Ingelheim Recent Development
  • 11.3 Brammer Bio
    • 11.3.1 Brammer Bio Corporation Information
    • 11.3.2 Brammer Bio Description, Business Overview and Total Revenue
    • 11.3.3 Brammer Bio Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Brammer Bio Viral Vector Vaccines Products Offered
    • 11.3.5 Brammer Bio Recent Development
  • 11.4 Creative Biogene
    • 11.4.1 Creative Biogene Corporation Information
    • 11.4.2 Creative Biogene Description, Business Overview and Total Revenue
    • 11.4.3 Creative Biogene Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Creative Biogene Viral Vector Vaccines Products Offered
    • 11.4.5 Creative Biogene Recent Development
  • 11.5 GE Healthcare
    • 11.5.1 GE Healthcare Corporation Information
    • 11.5.2 GE Healthcare Description, Business Overview and Total Revenue
    • 11.5.3 GE Healthcare Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 GE Healthcare Viral Vector Vaccines Products Offered
    • 11.5.5 GE Healthcare Recent Development
  • 11.6 Pfizer
    • 11.6.1 Pfizer Corporation Information
    • 11.6.2 Pfizer Description, Business Overview and Total Revenue
    • 11.6.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Pfizer Viral Vector Vaccines Products Offered
    • 11.6.5 Pfizer Recent Development
  • 11.7 Sanofi
    • 11.7.1 Sanofi Corporation Information
    • 11.7.2 Sanofi Description, Business Overview and Total Revenue
    • 11.7.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Sanofi Viral Vector Vaccines Products Offered
    • 11.7.5 Sanofi Recent Development
  • 11.1 Advanced Bioscience Laboratories
    • 11.1.1 Advanced Bioscience Laboratories Corporation Information
    • 11.1.2 Advanced Bioscience Laboratories Description, Business Overview and Total Revenue
    • 11.1.3 Advanced Bioscience Laboratories Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Advanced Bioscience Laboratories Viral Vector Vaccines Products Offered
    • 11.1.5 Advanced Bioscience Laboratories Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Viral Vector Vaccines Market Estimates and Projections by Region
    • 12.1.1 Global Viral Vector Vaccines Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Viral Vector Vaccines Revenue Forecast by Regions 2021-2026
  • 12.2 North America Viral Vector Vaccines Market Size Forecast (2021-2026)
    • 12.2.1 North America: Viral Vector Vaccines Sales Forecast (2021-2026)
    • 12.2.2 North America: Viral Vector Vaccines Revenue Forecast (2021-2026)
    • 12.2.3 North America: Viral Vector Vaccines Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Viral Vector Vaccines Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Viral Vector Vaccines Sales Forecast (2021-2026)
    • 12.3.2 Europe: Viral Vector Vaccines Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Viral Vector Vaccines Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Viral Vector Vaccines Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Viral Vector Vaccines Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Viral Vector Vaccines Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Viral Vector Vaccines Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Viral Vector Vaccines Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Viral Vector Vaccines Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Viral Vector Vaccines Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Viral Vector Vaccines Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Viral Vector Vaccines Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Viral Vector Vaccines Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Viral Vector Vaccines Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Viral Vector Vaccines Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter’s Five Forces Analysis
  • 13.5 Primary Interviews with Key Viral Vector Vaccines Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Viral Vector Vaccines Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source

    Viral vector vaccines combine many of the positive qualities of DNA vaccines with those of live attenuated vaccines.
    Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Viral Vector Vaccines market in 2020.
    COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
    The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
    This report also analyses the impact of Coronavirus COVID-19 on the Viral Vector Vaccines industry.
    Based on our recent survey, we have several different scenarios about the Viral Vector Vaccines YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Viral Vector Vaccines will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
    With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Viral Vector Vaccines market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Viral Vector Vaccines market in terms of both revenue and volume.
    Players, stakeholders, and other participants in the global Viral Vector Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on sales (volume), revenue and forecast by each application segment in terms of sales and revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
    Sales and Pricing Analyses
    Readers are provided with deeper sales analysis and pricing analysis for the global Viral Vector Vaccines market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.
    In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.
    Regional and Country-level Analysis
    The report offers an exhaustive geographical analysis of the global Viral Vector Vaccines market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.
    Competition Analysis
    In the competitive analysis section of the report, leading as well as prominent players of the global Viral Vector Vaccines market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Viral Vector Vaccines market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Viral Vector Vaccines market.
    The following manufacturers are covered in this report:
    Advanced Bioscience Laboratories
    Boehringer Ingelheim
    Brammer Bio
    Creative Biogene
    GE Healthcare
    Pfizer
    Sanofi
    ...
    Viral Vector Vaccines Breakdown Data by Type
    Adenovirus
    Fowlpox Virus
    Attenuated Yellow Fever
    Vaccinia Virus Vectors
    Others
    Viral Vector Vaccines Breakdown Data by Application
    Hospitals
    Clinics
    Others

    Buy now